Hayfever Relief For Adults (Beclometasone Dipropionate)

Hayfever Relief For Adults is indicated for the symptomatic treatment of allergic rhinitis in adults.

• Relief of nasal congestion, sneezing and itching caused by seasonal allergens.
• Management of persistent or intermittent hay‑fever symptoms when avoidance measures are insufficient.
• Adjunct therapy for patients who have not achieved adequate control with oral antihistamines alone.
• Use as part of a comprehensive allergy management plan, including environmental control.

Side effects reported with beclometasone dipropionate nasal spray are generally mild, but serious reactions can occur.

Common

• Nasal irritation or burning sensation.
• Dryness of the nasal mucosa.
• Minor nosebleeds (epistaxis).
• Throat irritation or cough.

Serious

• Signs of adrenal suppression such as fatigue, weakness or unexplained weight loss.
• Severe or persistent nosebleeds.
• Allergic reactions including swelling of the face, lips or throat, and difficulty breathing.

Before using Hayfever Relief For Adults, consider the following precautions to ensure safe and effective treatment.

• Do not use if you have a known hypersensitivity to beclometasone dipropionate or any other component of the spray.
• Limit use to the recommended duration; prolonged therapy may increase the risk of local or systemic corticosteroid effects.
• Monitor for signs of nasal septum perforation, especially with excessive or improper administration.
• Caution in patients with uncontrolled diabetes, glaucoma, or cataracts, as corticosteroids can exacerbate these conditions.
• Discuss use with a healthcare professional during pregnancy or breastfeeding; the product is classified as pregnancy category B.
• Avoid use in children unless specifically prescribed, as safety and efficacy have not been established for pediatric populations.

Beclometasone dipropionate may interact with other medications; review the following categories.

Avoid

• Concurrent use of potent systemic corticosteroids (e.g., oral prednisolone) that could increase systemic glucocorticoid exposure.
• Nasal decongestant sprays containing oxymetazoline or phenylephrine when used excessively, which may worsen nasal mucosal irritation.

Use with caution

• Antifungal agents such as ketoconazole that inhibit CYP3A4 and could raise local steroid levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) that may reduce the effectiveness of the nasal steroid.
• Immunosuppressive drugs, including biologics, where additional immunosuppression could increase infection risk.
• Vaccines, particularly live attenuated vaccines, as systemic absorption of steroids might diminish immune response.